Stock Scorer

Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences, Inc. reported revenue of 1.5M USD for the quarter ending 30 June 2026, down 43.8% from 2.7M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.5M -43.8%
Operating Income Q2 '26 · ending 30 June 2026 -25.3M —
Net Income Q2 '26 · ending 30 June 2026 -24.3M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -22.8M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -22.8M —
Shares Outstanding Q2 '26 · ending 30 June 2026 101M +9.0%
EPS Q2 '26 · ending 30 June 2026 -1.08 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 11.2M-148.3M-148.1M-112.4M
20242024-12-31 10M-166.6M-149.1M-143.1M
20232023-12-31 34.5M-116.1M-102.1M-104.9M
20222022-12-31 13.9M-106.4M-99.4M-97.4M
20212021-12-31 9.6M-67M-66.9M-34.6M
20202020-12-31 12.4M-36.1M-34.3M-33.5M
20192019-12-31 5.8M-34.3M-23.4M-32.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.5M
Q1 '262026-03-312.4M
Q4 '252025-12-313.9M
Q3 '252025-09-302.2M
Q2 '252025-06-302.7M
Q1 '252025-03-312.4M
Q4 '242024-12-312.1M
Q3 '242024-09-302M
Q2 '242024-06-303.5M
Q1 '242024-03-312.4M
Q4 '232023-12-313.6M
Q3 '232023-09-3023.7M
Q2 '232023-06-303.8M
Q1 '232023-03-313.5M
Q4 '222022-12-313.7M
Q3 '222022-09-303.3M
Q2 '222022-06-304.2M
Q1 '222022-03-312.7M
Q4 '212021-12-312.6M
Q3 '212021-09-304M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-25.3M
Q1 '262026-03-31-26.3M
Q4 '252025-12-31-28.5M
Q3 '252025-09-30-29.4M
Q2 '252025-06-30-47.6M
Q1 '252025-03-31-42.9M
Q4 '242024-12-31-38.9M
Q3 '242024-09-30-38.2M
Q2 '242024-06-30-43.5M
Q1 '242024-03-31-46M
Q4 '232023-12-31-37.4M
Q3 '232023-09-30-14.6M
Q2 '232023-06-30-32.9M
Q1 '232023-03-31-31.1M
Q4 '222022-12-31-30.6M
Q3 '222022-09-30-26.5M
Q2 '222022-06-30-28.4M
Q1 '222022-03-31-20.9M
Q4 '212021-12-31-20.4M
Q3 '212021-09-30-18.6M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-24.3M
Q1 '262026-03-31-25.1M
Q4 '252025-12-31-26.5M
Q3 '252025-09-30-27.5M
Q2 '252025-06-30-54.1M
Q1 '252025-03-31-40M
Q4 '242024-12-31-35.5M
Q3 '242024-09-30-34.7M
Q2 '242024-06-30-37.7M
Q1 '242024-03-31-41.2M
Q4 '232023-12-31-34.5M
Q3 '232023-09-30-10M
Q2 '232023-06-30-29.5M
Q1 '232023-03-31-28M
Q4 '222022-12-31-27M
Q3 '222022-09-30-26.6M
Q2 '222022-06-30-26.7M
Q1 '222022-03-31-19.1M
Q4 '212021-12-31-18.5M
Q3 '212021-09-30-21M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-22.8M
Q1 '262026-03-31-27M
Q4 '252025-12-31-20.8M
Q3 '252025-09-30-25.2M
Q2 '252025-06-30-28.3M
Q1 '252025-03-31-36.7M
Q4 '242024-12-31-35.5M
Q3 '242024-09-30-32.7M
Q2 '242024-06-30-32.9M
Q1 '242024-03-31-37.2M
Q4 '232023-12-31-21.4M
Q3 '232023-09-30-28.8M
Q2 '232023-06-30-15.2M
Q1 '232023-03-31-27.9M
Q4 '222022-12-31-25M
Q3 '222022-09-30-22.4M
Q2 '222022-06-30-21.9M
Q1 '222022-03-31-21.7M
Q4 '212021-12-31-21.4M
Q3 '212021-09-30-15M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-22.8M
Q1 '262026-03-31-27.1M
Q3 '252025-09-30-25.3M
Q2 '252025-06-30-28.7M
Q1 '252025-03-31-37.8M
Q4 '242024-12-31-36M
Q3 '242024-09-30-33.3M
Q2 '242024-06-30-35.1M
Q1 '242024-03-31-38.7M
Q4 '232023-12-31-23.7M
Q3 '232023-09-30-33.5M
Q2 '232023-06-30-17.7M
Q1 '232023-03-31-30M
Q4 '222022-12-31-26.8M
Q3 '222022-09-30-23.7M
Q2 '222022-06-30-24.5M
Q1 '222022-03-31-22.4M
Q4 '212021-12-31-22.1M
Q3 '212021-09-30-15.9M
Q2 '212021-06-30-17M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30101M
Q1 '262026-03-3195.9M
Q3 '252025-09-3093.3M
Q2 '252025-06-3093M
Q1 '252025-03-3192.7M
Q3 '242024-09-3090.5M
Q2 '242024-06-3090.3M
Q1 '242024-03-3189.3M
Q3 '232023-09-3083.8M
Q2 '232023-06-3061.4M
Q1 '232023-03-3161.2M
Q3 '222022-09-3060.9M
Q2 '222022-06-3060.8M
Q1 '222022-03-3160.5M
Q3 '212021-09-3045.9M
Q2 '212021-06-3010.3M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.08
Q1 '262026-03-31-1.42
Q4 '252025-12-31-1.59
Q3 '252025-09-30-1.70
Q2 '252025-06-30-1.78
Q1 '252025-03-31-1.62
Q4 '242024-12-31-1.65
Q3 '242024-09-30-1.66
Q2 '242024-06-30-1.40
Q1 '242024-03-31-1.46
Q4 '232023-12-31-1.46
Q3 '232023-09-30-1.51
Q2 '232023-06-30-1.83
Q1 '232023-03-31-1.79
Q4 '222022-12-31-1.65
Q3 '222022-09-30-1.51
Q2 '222022-06-30-1.53
Q1 '222022-03-31-2.48
Q4 '212021-12-31-3.55
Q3 '212021-09-30-4.92